• 25 June 2018

    The challenges of using stem cells in neurology

    The development of stem-cell based therapies has been slow even though there are many theoretical applications and benefits associated with these therapies. The challenges of translating potential drugs from clinical...

  • 20 June 2018

    Another BACE inhibitor fails in phase III trials

    On June 12, AstraZeneca and Eli Lilly terminated their two Phase III clinical trials of oral amyloid targeting β-secretase (BACE) inhibitor lanabecestat in Alzheimer’s disease (AD). The partners made the...

  • 22 May 2018

    PD-L1 biomarker makes a comeback in bladder cancer

    PD-L1 has long been dismissed as a viable biomarker in advanced bladder cancer, given that numerous late-stage clinical trials of PD-1/L1 inhibitors in the disease have reported clinical benefit even...

  • 8 May 2018

    Barriers impede biosimilar market entry into the US

    Back in 2010, the FDA implemented the Biologics Price Competition and Innovation Act (BPCIA) as part of the Affordable Care Act (ACA), which created an abbreviated pathway for biosimilar drug...